Simcere Pharma Q2 Profit Declines - Quick Facts

(RTTNews) - Simcere Pharmaceutical Group (SCR) reported its preliminary second-quarter results. Net income attributable to shareholder from continuing operations declined to RMB 8.23 million or RMB 0.08 per share, from RMB 19.39 million or RMB 0.18 per share, prior year. Earnings per ADS attributable to Simcere from continuing operations was RMB 0.15 for the quarter.

Net income attributable to Simcere shareholder was RMB 22.74 million, compared to RMB 26.97 million prior year. Total revenue decreased to RMB 482.995 million, from RMB 498.064 million prior year.